NCT00593463

Drug Discrimination in Methadone-Maintained Humans Study 1

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Arkansas · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.

Conditions

• Drug Dependence

Interventions

Type	Name	Description
DRUG	Cycloserine	Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
DRUG	Diltiazem	Diltiazem: 30, 60, 120 mg oral capsule may possibly be
DRUG	Gabapentin	Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
DRUG	Isradipine	Isradipine: 5, 10 mg oral capsule may possibly be given
DRUG	Naloxone	Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
DRUG	Nifedipine	Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
DRUG	Placebo	Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
DEVICE	Saline	Saline: I.M. injection may possibly be given
DRUG	Verapamil	Verapamil: 30, 60, 120 mg oral capsule may possibly be given

Timeline

• Start date: 2006-09-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2008-01-15
• Last updated: 2011-03-11

Locations

1 site across 1 country: United States